
    
      CT-P59 is a monoclonal antibody targeted against SARS-CoV-2 spike RBD as a treatment for SARS
      CoV 2 infection. CT-P59 is currently being developed by the Sponsor as a potential treatment
      for SARS-CoV-2 infection. In this study, safety, tolerability and virology of CT-P59 will be
      evaluated in patient with mild symptoms of SARS-CoV-2 Infection.
    
  